Randomized Phase 3 Study of Panitumumab With FOLFIRI vs. FOLFIRI Alone as Second-Line Treatment in Patients With Metastatic Colorectal Cancer

Lignende værker

• Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
  af: Ottaiano, Alessandro, et al.
  Udgivet: (2019)
• Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
  Udgivet: (2014)
• A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
  af: Liu, Yuguo, et al.
  Udgivet: (2015)
• XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer
  af: CUI, CHENGXU, et al.
  Udgivet: (2014)
• Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
  af: Bennett, L, et al.
  Udgivet: (2011)